Sanofi Expects Dengue Vaccine Clinical Trial Results In September

Reuters: Sanofi faces make-or-break verdict on big dengue vaccine bet
“Sanofi expects final clinical results for its vaccine against dengue by late September, the French drugmaker’s project leader has told Reuters, and has already gambled on starting production despite some disappointing early trials data. Sanofi has invested more than one billion euros in the project and is hoping to become the first drugmaker to sell such a shot next year after two decades of research on the world’s fastest-growing tropical disease, for which there is no preventative treatment…” (Huet/Mennella, 3/25).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.